Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28118230 | 0.78 | ALDH1A1 (0.33) | ALDH1A1HPGDHIF1APGD | |
| SCHEMBL2124558 | 0.77 | CPA1 (0.39) | TP53CPA1ALDH1A1HPGDHIF1A | |
| SCHEMBL158249 | 0.75 | SMN1; SMN2 (0.37) | ALDH1A1HPGDHIF1ATDP1 | |
| SCHEMBL459446 | 0.74 | — | — | |
| Cadaverine Tartrate SCHEMBL5389202 | 0.73 | TSHR (0.62) | TSHRTP53CPA1ALDH1A1HIF1A | |
| Cadaverine Tartrate SCHEMBL9222315 | 0.73 | TSHR (0.62) | TSHRTP53CPA1ALDH1A1HIF1A | |
| Cadaverine Tartrate SCHEMBL20636592 | 0.73 | TSHR (0.62) | TSHRTP53CPA1ALDH1A1HIF1A | |
| SCHEMBL11045907 | 0.73 | ALDH1A1 (0.35) | ALDH1A1HPGDHIF1A | |
| SCHEMBL9512718 | 0.73 | — | — | |
| SCHEMBL1980632 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112990-A1 | Methods for producing and separating erythro- and threo-2-hydroxy-3-nitrobutanoic acid compounds | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-07-04 | — | — | EP | claimed |
| US-20010005762-A1 | Reacting in a solvent, a 2-hydroxy-3-nitrobutanoic acid compound with not less than 1 equivalent of a base to isomerize the erythro compound into threo compound or the threo compound into the erythro compound | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-06-28 | — | — | US | claimed |
| JP-2001247488-A | METHOD FOR PRODUCING ERYTHRO- OR THREO-FORM OF 2- HYDROXY-3-NITROBUTYRIC ACID COMPOUND, AND METHOD FOR SEPARATING ERYTHRO- AND THREO-FORM OF 2-HYDROXY-3- NITROBUTYRIC ACID COMPOUND | SUMIKA FINE CHEMICALS CO LTD | 2001-09-11 | — | — | JP | disclosed |
| EP-1112990-A1 | Methods for producing and separating erythro- and threo-2-hydroxy-3-nitrobutanoic acid compounds | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1112990-A1 | Methods for producing and separating erythro- and threo-2-hydroxy-3-nitrobutanoic acid compounds | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-1112990-A1 | Methods for producing and separating erythro- and threo-2-hydroxy-3-nitrobutanoic acid compounds | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| US-20010005762-A1 | Reacting in a solvent, a 2-hydroxy-3-nitrobutanoic acid compound with not less than 1 equivalent of a base to isomerize the erythro compound into threo compound or the threo compound into the erythro compound | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-06-28 | — | — | US | disclosed |
| US-20010005762-A1 | Reacting in a solvent, a 2-hydroxy-3-nitrobutanoic acid compound with not less than 1 equivalent of a base to isomerize the erythro compound into threo compound or the threo compound into the erythro compound | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-06-28 | — | — | US | disclosed |
| US-20010005762-A1 | Reacting in a solvent, a 2-hydroxy-3-nitrobutanoic acid compound with not less than 1 equivalent of a base to isomerize the erythro compound into threo compound or the threo compound into the erythro compound | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005762-A1 | Reacting in a solvent, a 2-hydroxy-3-nitrobutanoic acid compound with not less than 1 equivalent of a base to isomerize the erythro compound into threo compound or the threo compound into the erythro compound | NHERF1, SLC5A1, SLC9B2 | TSHR 1959/4885TP53 4780/4885CPA1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.